Realisation of c£1.5 million on sale of shares in Incanthera plc

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, announces that it has realised gross proceeds of c£1.5 million on the sale of its entire holding of c9.9 million shares in Incanthera plc.

Following this transaction, ImmuPharma retains c7.3 million warrants in Incanthera plc which have an exercise price of 9.5p and exercise expiry date of 6 September 2024.

To download announcement click here